Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Halozyme (HALO)

Halozyme Announces Senior Management Update; COO Cortney Caudill Departs

Neutral Impact 4 of 5 leadership Written later

Halozyme Therapeutics said on June 30, 2026 that it updated its senior management structure and that Cortney Caudill, Senior Vice President and Chief Operating Officer, is leaving the company. The filing does not give a replacement, a reason for the departure, or any financial effect, so the direct impact on shareholders is unclear from this document alone.

Key points

  • Cortney Caudill, Senior Vice President and Chief Operating Officer, departed the company, as announced June 30, 2026
  • Halozyme announced an update to its senior management structure on June 30, 2026, without details in the filing
  • The filing does not name a successor or describe the reason for the departure

The filing

CompanyHalozyme (HALO)
Form8-K, current report
Filed with the SECJul 2, 2026, 4:10 PM ET
Accession number0001159036-26-000088

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:12 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 02, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.